摘要
第三代芳香化酶抑制剂(aromatase inhibitors,AIs)是绝经后激素受体阳性乳腺癌患者内分泌治疗的标准药物。芳香化酶抑制剂相关骨关节症状(aromatase inhibitor-associated musculoskeletal symptoms,AIMSS)是AIs常见的不良反应之一,严重影响患者的生活质量和对内分泌治疗的依从性。目前AIMSS的发病机制和有效的治疗方法尚处于研究探索阶段。本文主要针对AIMSS的发病情况、临床特征、发病机制和治疗进展进行综述。
Third-generation aromatase inhibitors （AIs） have been considered as standard adjuvant endocrine therapy for hor- mone- responsive breast cancer in postmenopausal women. Aromatase inhibitor-associated musculoskeletal symptoms （AIMSS） are prevalent among patients undergoing AI therapy; these symptoms result in reduced quality of life and poor dependence to AI treatment. The mechanisms mediating AIMSS and the effective management of AIMSS have not been extensively investigated. This article re- views the incidence, clinical characteristics, possible mechanisms, and treatment of AIMSS.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2015年第21期1067-1070,共4页
Chinese Journal of Clinical Oncology
基金
北京市科学技术委员会"中医药提升恶性肿瘤疗效系统研究"项目(编号:D131100002213001)资助~~
关键词
乳腺癌
芳香化酶抑制剂
关节痛
肌肉骨骼症状
breast cancer, aromatase inhibitors, arthralgia, musculoskeletal symptoms
